JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB146939

NVS-PAK1-1, PAK1 inhibitor

Be the first to review this product! Submit a review

|

(1 Publication)

MW 479.93 g/mol, Purity >98%. NVS-PAK1-1 is a potent allosteric inhibitor of p21-activated kinase PAK1. It has an IC50 value of 5 nM for dephoshorylated PAK1 and 6 nM for phosphorylated PAK1 in an in vitro assay. It is more than 50-fold more active against PAK1 than against PAK2. NVS-PAK1-1 is highly selective in a panel of 442 kinases. NVS-PAK1-1 potently inhibits PAK1 autophosphorylation in cell-based assays.

Key facts

CAS number

1783816-74-9

Purity

>98%

Form

Lyophilized

form

Molecular weight

479.93 g/mol

Molecular formula

C<sub>2</sub><sub>3</sub>H<sub>2</sub><sub>5</sub>ClF<sub>3</sub>N<sub>5</sub>O

Nature

Synthetic

Solubility

Soluble in ethanol to 100 mM

Soluble in DMSO to 100 mM

Biological description

NVS-PAK1-1 is a potent allosteric inhibitor of p21-activated kinase PAK1. It has an IC50 value of 5 nM for dephoshorylated PAK1 and 6 nM for phosphorylated PAK1 in an in vitro assay. It is more than 50-fold more active against PAK1 than against PAK2. NVS-PAK1-1 is highly selective in a panel of 442 kinases. NVS-PAK1-1 potently inhibits PAK1 autophosphorylation in cell-based assays.

Isomeric smiles

O=C(NC(C)C)N4CC[C@H](NC1=NC3CC(F)CCC3N(CC(F)F)C2CCC(CL)CC12)C4

InChi

InChI=1S/C23H25ClF3N5O/c1-13(2)28-23(33)31-8-7-16(11-31)29-22-17-9-14(24)3-5-19(17)32(12-21(26)27)20-6-4-15(25)10-18(20)30-22/h3-6,9-10,13,16,21H,7-8,11-12H2,1-2H3,(H,28,33)(H,29,30)/t16-/m0/s1

IUPAC Name

(S)-3-(2-Chloro-5-(2,2-difluoroethyl)-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11-ylamino)-N-isopropylpyrrolidine-1-carboxamide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

ACS medicinal chemistry letters 6:776-81 PubMed26191365

2015

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

Applications

Unspecified application

Species

Unspecified reactive species

Alexei S Karpov,Payman Amiri,Cornelia Bellamacina,Marie-Helene Bellance,Werner Breitenstein,Dylan Daniel,Regis Denay,Doriano Fabbro,Cesar Fernandez,Inga Galuba,Stephanie Guerro-Lagasse,Sascha Gutmann,Linda Hinh,Wolfgang Jahnke,Julia Klopp,Albert Lai,Mika K Lindvall,Sylvia Ma,Henrik Möbitz,Sabina Pecchi,Gabriele Rummel,Kevin Shoemaker,Joerg Trappe,Charles Voliva,Sandra W Cowan-Jacob,Andreas L Marzinzik
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com